Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Carboplatin
Drug ID BADD_D00364
Description Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma.[L32253] Early clinical studies of carboplatin were performed in 1982.[A230523] Carboplatin was developed as an analog of [cisplatin] with reduced nephrotoxicity and vomiting.[A230463,A230523] Carboplatin was granted FDA approval on 3 March 1989.[L32248]
Indications and Usage Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma.[L32253] Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.[L32253]
Marketing Status approved
ATC Code L01XA02
DrugBank ID DB00958
KEGG ID D01363
MeSH ID D016190
PubChem ID 426756
TTD Drug ID D0X7HM
NDC Product Code 0703-4239; 55150-386; 63323-172; 68083-191; 63592-0271; 61703-339; 0703-4244; 0703-4246; 72659-863; 50742-447; 69448-005; 61703-600; 55150-334; 61703-262; 61703-360; 71288-100; 49812-0010; 16729-295; 55150-333; 61703-150; 68083-193; 68554-0084; 68083-190; 68083-192; 53104-7570; 54875-0002; 50742-448; 55150-335; 0703-4248
UNII BG3F62OND5
Synonyms Carboplatin | cis-Diammine(cyclobutanedicarboxylato)platinum II | CBDCA | Paraplatin | Paraplatine | Platinwas | Ribocarbo | Carboplat | Neocarbo | Carbosin | Carbotec | Ercar | JM-8 | JM 8 | JM8 | Nealorin | NSC-241240 | NSC 241240 | NSC241240 | Blastocarb
Chemical Information
Molecular Formula C6H12N2O4Pt
CAS Registry Number 41575-94-4
SMILES C1CC(C1)(C(=O)O)C(=O)O.[NH2-].[NH2-].[Pt+2]
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hyporesponsive to stimuli17.02.05.0570.000224%Not Available
Hyponatraemic seizure14.05.04.008; 17.12.03.0250.000224%Not Available
Pseudocellulitis23.03.04.0400.000112%Not Available
Toxic leukoencephalopathy17.13.02.012; 12.03.01.0590.000336%Not Available
Pharyngeal paraesthesia22.04.05.018; 17.02.06.0350.000336%Not Available
Adult failure to thrive08.01.01.014; 19.15.02.009; 14.03.02.0200.000112%Not Available
Tumour pseudoprogression16.32.03.0320.000224%Not Available
Intracranial mass17.11.01.0170.000112%Not Available
Acute megakaryocytic leukaemia16.01.05.007; 01.10.05.0070.000112%Not Available
Administration site extravasation12.07.04.019; 08.02.04.0190.000839%Not Available
Astrocytoma malignant17.20.02.007; 16.30.02.0070.000112%Not Available
Chronic coronary syndrome24.04.04.028; 02.02.02.0240.000168%Not Available
Colorectal adenoma16.05.02.009; 07.20.01.0190.000168%Not Available
Cross sensitivity reaction10.01.01.0360.000168%Not Available
Dilated cardiomyopathy02.04.01.0170.000168%Not Available
Ganglioglioma17.20.01.011; 16.30.01.0110.000112%Not Available
Glioneuronal tumour17.20.01.012; 16.30.01.0120.000112%Not Available
Hepatic cytolysis09.01.07.0360.000560%Not Available
Immune thrombocytopenia01.08.01.013; 10.02.01.0830.000112%Not Available
Inadequate analgesia12.02.20.006; 08.06.01.0400.000224%Not Available
Infusion related hypersensitivity reaction12.02.05.055; 10.01.03.0580.000448%Not Available
Injection site macule23.03.03.087; 12.07.03.064; 08.02.03.0640.000112%Not Available
Intermenstrual bleeding21.01.01.0150.000280%Not Available
Intra-abdominal fluid collection21.07.04.014; 07.07.01.0140.000112%Not Available
Lung opacity22.12.01.0060.000112%Not Available
Metastatic lymphoma16.20.01.007; 01.12.01.0070.000112%Not Available
Myelosuppression01.03.03.0150.000728%Not Available
Normocytic anaemia01.03.02.0220.000224%Not Available
Obstructive nephropathy20.05.03.0240.000112%Not Available
Orbital myositis15.05.01.014; 06.04.11.0050.000224%Not Available
The 20th Page    First    Pre   20 21    Next   Last    Total 21 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene